Three members of an independent FDA advisory panel say they received advanced information ahead...
Three members of an independent FDA advisory panel say they received advanced information ahead of U.S. regulators in May 2010 regarding the rejection of a drug from InterMune (ITMN -2.5%), which is now at the heart of a trading investigation of SAC Capital. ITMN’s shares fell 5.4% the day before the company announced the rejection. However, others at the FDA were also aware of the rejection too, and there’s no evidence the 11 panelists did anything wrong.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs